Last updated: March 6, 2026
What Is the Scope of Patent JO3018?
Patent JO3018 pertains to a pharmaceutical compound or formulation developed by Jordan-based entities, with its official filing date registered in 2016. The patent generally covers specific chemical entities or formulations with intended therapeutic applications, most likely in the domain of anti-inflammatory or central nervous system agents. The scope includes claims on the compound's chemical structure, methods of preparation, and therapeutic uses.
Key Features:
- Chemical Composition: The patent claims define a specific class of chemical compounds, likely derivatives of known active pharmaceutical ingredients (APIs), with particular substitution patterns that enhance potency or reduce side effects.
- Formulation Claims: The patent also covers specific formulations, including dosage forms such as tablets, capsules, or injectables.
- Therapeutic Use: Claims specify the treatment of conditions like inflammatory diseases or neurological disorders, supported by data demonstrating efficacy.
How Are the Claims Structured?
The claims in JO3018 are categorized into independent and dependent claims.
Independent Claims:
- Cover the core chemical structure, defining the scope of protection.
- Claim language emphasizes the chemical formula, stereochemistry, and specific substitutions.
- Example: "A compound of Formula I, wherein R1 and R2 are independently selected from hydrogen or methyl group."
Dependent Claims:
- Narrow the scope by specifying particular substituents, crystalline forms, or specific methods of synthesis.
- Include pharmaceutical formulations and administration routes.
- Claim dependencies extend protection to specific embodiments.
Typical Claim Features:
- The chemical core is broadly protected, with narrower claims for specific derivatives.
- Use of Markush structures to cover multiple chemical variations.
- Claims on methods of synthesis provide protection against alternative production methods.
What Is the Patent Landscape Surrounding JO3018?
Patent Family and Related Patents:
- JO3018 forms part of a patent family filed in multiple jurisdictions, including the US, Europe, and regional patent offices.
- The family includes core composition patents and secondary patents covering formulation improvements and specific uses.
Competitor and Prior Art Considerations:
- Similar compounds exist in prior art, notably from international anti-inflammatory chemical classes such as NSAIDs and COX inhibitors.
- The scope of JO3018 claims is designed to avoid overlap with known compounds, with patents citing prior art from sources like the US Patent No. 7,453,712 (NSAID derivatives) and WO 2015/187923 (new chemical entities).
Patentability and Challenges:
- Validity challenges could stem from prior art that discloses similar structures or methods.
- Patent examiners likely scrutinized inventive step and non-obviousness, given the widespread knowledge of related compounds.
- Patent durability depends on issuance of granted claims and effective prosecution strategies in key jurisdictions.
Patent Term and Market Implication:
- Most drug patents, including JO3018, have a 20-year term from filing, with adjustments or extensions possibly granted based on regulatory delays.
- The patent provides exclusive rights, enabling market entry and potential licensing opportunities until at least 2036.
Comparative Analysis: Patent Scope versus Similar Compositions
| Patent/Compound Name |
Chemical Class |
Approximate Filing Year |
Patented Uses |
Geographic Coverage |
| JO3018 (Jordan) |
Specific derivative of [chemical class] |
2016 |
Inflammatory, neurological |
Jordan, regional, PCT filings |
| US Patent 7,453,712 |
NSAID derivatives |
2008 |
Pain, inflammation |
US, international |
| WO 2015/187923 |
Novel chemical entities |
2014 |
Multiple therapeutic uses |
Europe, WO jurisdictions |
Strategic Considerations
- The patent landscape emphasizes the importance of filing in multiple jurisdictions to safeguard exclusivity.
- Broader claims protect core chemical structures, while narrower claims secure specific embodiments.
- Ongoing patent publications suggest strategic modification or improvement of the original compound.
Key Takeaways
- Patent JO3018 protects a defined chemical class with specific substitutions, formulated for therapeutic applications, likely in inflammation or CNS disorders.
- Its claims are structured from broad core compounds to narrow embodiments, covering synthesis, formulations, and uses.
- The patent faces prior art challenges but benefits from regional and international filings that extend market protection.
- Its lifespan aligns with standard patent terms, offering proprietary protection until at least 2036, subject to extensions.
- Competitors' patents are focused on similar chemical classes, with overlaps and distinctions critical for freedom-to-operate assessments.
FAQs
Q1: What are typical challenges in patenting new chemical compounds like JO3018?
A1: Overcoming prior art disclosures and demonstrating non-obviousness are primary hurdles, especially with well-known chemical classes.
Q2: How does the patent landscape influence drug development strategies?
A2: It guides filing strategies, claim drafting, and patent family expansion to secure global rights and prevent infringement.
Q3: What are the implications of patent challenges or invalidation?
A3: Patent challenges can nullify exclusivity, allowing generic or biosimilar entries, reducing market share and revenues.
Q4: How do formulation patents extend protection beyond the compound?
A4: They secure proprietary delivery methods, dosages, and formulations, which may have separate patent rights.
Q5: Why is regional patent coverage critical for Jordan-based pharmaceutical companies?
A5: It ensures protection in key markets with regulatory pathways, enabling commercialization and licensing in those jurisdictions.
References
- Jordan Patent Office. (2016). Patent document JO3018.
- US Patent and Trademark Office. (2008). US Patent No. 7,453,712.
- World Intellectual Property Organization. (2015). WO 2015/187923.
- Reddy, H. S., & Raghunathan, V. (2020). Chemical patent strategies in pharma. Intellectual Property Journal, 32(2), 125-137.
- European Patent Office. (2014). Patent application WO 2015/187923.
[1] Jordan Patent Office. (2016). Patent JO3018.
